Ardent Health (ARDT) CFO receives 61,081 performance-based stock units in grant

Rhea-AI Filing Summary

Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported an equity compensation award on Common Stock. He acquired 61,081 shares on March 11, 2026 at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.

According to the footnote, these shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units granted on July 18, 2024, and will vest on December 31, 2026 if he remains in service through that date. Following this award, he directly holds 272,228 Common Stock shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LUMSDAINE ALFRED

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	61,081	$0.00	--

Holdings After Transaction: Common Stock — 272,228 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUMSDAINE ALFRED

(Last) (First) (Middle)

340 SEVEN SPRINGS WAY, SUITE 100

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		A		61,081(1)	A	$0	272,228	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares earned based on 2024 and 2025 performance under performance vesting restricted stock units awarded on July 18, 2024. Pursuant to the terms of the award, the shares will vest on December 31, 2026 contingent upon service through such date.

Remarks:

	/s/ Stephen C. Petrovich, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ardent Health (ARDT) CFO Alfred Lumsdaine report on this Form 4?

Ardent Health CFO Alfred Lumsdaine reported acquiring 61,081 shares of Common Stock as an equity award. The grant reflects performance-vesting restricted stock units, not an open-market purchase, and increased his direct holdings to 272,228 shares after the reported transaction.

Was the Ardent Health (ARDT) CFO’s Form 4 transaction a stock market purchase?

No, the transaction was not a market purchase. The Form 4 shows a code "A" grant, meaning 61,081 shares were acquired as a compensation award at a stated price of $0.00 per share, tied to prior performance and future service conditions.

How many Ardent Health (ARDT) shares does the CFO hold after this Form 4?

After the reported award, Alfred Lumsdaine directly holds 272,228 shares of Ardent Health Common Stock. This total reflects the addition of 61,081 granted shares reported on the Form 4 and represents his direct ownership position following the transaction.

What performance period applies to the Ardent Health (ARDT) CFO’s awarded shares?

The 61,081 shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units granted July 18, 2024. This links the equity award to company performance across those two years, as disclosed in the Form 4 footnote.

When do the Ardent Health (ARDT) CFO’s performance-vesting shares vest?

The awarded shares are scheduled to vest on December 31, 2026. Vesting is contingent upon Alfred Lumsdaine’s continued service through that date, meaning he must remain with Ardent Health to fully receive the benefit of the performance-based award.

What does transaction code "A" mean in the Ardent Health (ARDT) Form 4?

Transaction code "A" on the Form 4 indicates a grant, award, or other acquisition rather than a purchase on the open market. For Ardent Health, it reflects the CFO receiving 61,081 Common Stock shares as performance-based restricted stock unit compensation.